CLARIFICATION: Wyeth's Viviant Ph III trial

An article published in the September 22 issue of the Marketletter relating to a Phase III clinical trial with US drug major Wyeth's Viviant (bazedoxifene) is misleading, according to a spokesperson for the company, because - by saying it failed to meet "statistical significance" - this implied that the drug did not meet its primary endpoint of the study, new vertebral fracture.

In fact, she said, the research found that, in post-menopausal women with osteoporosis, bazedoxifene 20mg and 40mg and raloxifene 60mg reduced the risk of new vertebral fracture by 42%, 37% and 42%, respectively, relative to placebo. Additionally, bazedoxifene 20mg and raloxifene 60mg were equal in the reduction of new vertebral fracture (42%). We are pleased to provide this clarification for our readers.